You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
A Novel, Field-Deployable, Biomimetic Narcotics Detector for the Identification of Fentanyl and Other Synthetic OpioidsSBC: SEACOAST SCIENCE, INC. Topic: NIDA
AbstractThe alarming scope of the rapidly growing opioid epidemic has commanded the nation’s attention. The White House’s Council of Economic Advisers estimates that in 2015, the economic cost of the opioid crisis was over $504.0 billion (2.8% of GDP); and it is only expected to continue rising. Today, 1 in 5 fatalities amongst young adults is opioid related; with half a million fatal overdose ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Viewpoint Therapeutics, Inc. Topic: NEI
Open-angle glaucoma is the second leading cause of blindness worldwide, affecting nearly 70 million individuals. Nonsynonymous mutations in the myocilin gene lead to the most common hereditary form of open-angle glaucoma and account for 3-4% of all cases. Disease-causing mutations, localized to its olfactomedin domain (mOLF), destabilize the myocilin protein, leading to its misfolding and accumula ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: REELIN THERAPEUTICS, INC. Topic: 300
Abstract Factors that contribute to the onset of inflammatory bowel disease (IBD) remain incompletely understood. Although specific genetic factors may increase risk, most IBD cannot be readily explained based on genetics. Dysbiosis in intestinal microbiomes also has been implicated. Once IBD is established, chronic inflammation is a central hallmark and also a major target for therapy. Both forms ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
Development of an irreversible covalent inhibitor of FMS-like tyrosine kinase receptor 3 for treating acute myeloid leukemiaSBC: BRIDGENE BIOSCIENCES INC Topic: 102
PROJECT SUMMARY Acute myeloid leukemia (AML), a malignant disease of hematopoietic precursor cells in the bone marrow, is one of the most common cancers in adults accounting for 1% of all cancers. AML is typically diagnosed later in life with individuals 60 and older having a long-term survival rate of merely 5-15%. Cytogenic analysis of the abnormal cells at the time of diagnosis has proven to be ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Storx Technologies, Inc. Topic: NICHD
Project Summary Despite significant cost and clear evidence of health risks associated with Cesarean section surgeries, an unnecessarily large number of infants are delivered via Cesarean section (C- Section) surgeries. The high rate of C-section in the US, relative to globally accepted norms, and the associated additional cost and complications are in part, due to high false positive rate of intr ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Wildflower Biopharma Inc Topic: 102
Project Summary/Abstract Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in Western countries. Despite recent treatment advances, CLL remains incurable. In the era of emerging targeted therapies, disease progression and relapse increasingly are key challenges faced by CLL patients. Therefore, there is an ongoing need for the identification of targetable vulnerabilities in t ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
Portable Affordable Innovative and Smart Device-Coupled Electronic Fetal Monitoring System to Improve Rural Access to Obstetrics Services and Improve Outcomes in Rural CommunitiesSBC: Fetal Life, LLC Topic: 102
Obstetricians measure fetal heartrate (FHR) and uterine contractions to evaluate fetal health during pregnancy and labor. This monitoring is performed to decrease the development of complications while minimizing the need for unnecessary obstetric interventions and is especially important for women with high-risk pregnancies. However, many women, especially in rural areas, do not have the time or ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
RememberStuff: a dyadic-focused technology to support persons with Alzheimer's disease in the communitySBC: EPERTURE LLC Topic: NIA
Project Abstract An estimated 5.7 million Americans have Alzheimer’s disease or a related dementia (ADRD) and one in ten people age 65 or older show symptoms of Alzheimer’s disease. As ADRD progresses so does the level of dependency on others. As the disease progresses, higher levels of dependence in people with Alzheimer’s disease are associated with significantly increased burden and costs ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: SCRIBE BIOSCIENCES, INC. Topic: 400
PROJECT SUMMARY There is an increased interest in peptide medicines in pharmaceutical research and development (Randamp;D) because peptides are recognized as highly selective and efficacious, and at the same time relatively safe and well tolerated. Chemo-enzymatic peptide synthesis (CEPS) using peptide ligases features excellent purity and yield, thus becoming an attractive method to replace tradi ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Technology Commercialization Partners LLC Topic: NHLBI
ABSTRACT Pulmonary hypertension (PH) is a highly debilitating disease that affects about 1% of the global population, which increases up to 10% in individuals aged more than 65 years. The life expectancy for these patients is less than 10 years after diagnosis, and no specific drugs are available for pharmacologic treatment. Despite the introduction PDE5, prostacyclin analogs, and endothelin antag ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health